Name: Impact of Neo-Adjuvant Chemotherapy in Colon Cancer (en Inglés)
Price: 1514.41 MXN
Availability: InStock
Author: Talbi, Nabila ; Abid, Mourad
ISBN: 9786205868645

Envío gratis

portada Impact of Neo-Adjuvant Chemotherapy in Colon Cancer (en Inglés)

Formato

Libro Físico

Autor

Nabila Talbi

Mourad Abid

Editorial

Our Knowledge Publishing

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.9 x 15.2 x 0.6 cm

Peso

0.15 kg.

ISBN13

9786205868645

Categorías

Cuestiones generales de la medicina

Impact of Neo-Adjuvant Chemotherapy in Colon Cancer (en Inglés)

Nabila Talbi (Autor) · Mourad Abid (Autor) · Our Knowledge Publishing · Tapa Blanda

Libro Nuevo

$ 1,514.41

$ 2,524.01

Ahorras: $ 1,009.61

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 12 de Agosto y el Martes 20 de Agosto.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Impact of Neo-Adjuvant Chemotherapy in Colon Cancer (en Inglés)"

Surgery with adjuvant chemotherapy is currently the gold standard in the management of locally advanced non-metastatic colon cancer. However, a peri-operative strategy is beginning to emerge. The aim of this randomized trial is to report a series of 110 patients operated on for locally advanced non-metastatic colon cancer with evaluation of the impact of neo-adjuvant chemotherapy versus primary surgery in terms of overall survival and recurrence-free survival, with the quality of the complete surgery and histological tumor regression as well as postoperative morbidity and mortality as endpoints. The results show a benefit of neoadjuvant chemotherapy on the quality of surgical excision by down sizing as well as a reduction of major postoperative morbidity and on the anatomopathological results by down staging and partial histological response. There seems to be a superiority of neoadjuvant chemotherapy in terms of median overall survival and recurrence-free survival. This new peri-operative strategy seems to provide tumor control. It would be a kind of pre-enabling for surgery.